Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-1366.46%
operating margin TTM
-1542.63%
revenue TTM
73.83 Million
revenue per share TTM
0.64$
valuation ratios | |
|---|---|
| pe ratio | -0.57 |
| peg ratio | -0.01 |
| price to book ratio | 0.33 |
| price to sales ratio | 7.76 |
| enterprise value multiple | -0.31 |
| price fair value | 0.33 |
profitability ratios | |
|---|---|
| gross profit margin | -189.23% |
| operating profit margin | -1542.63% |
| pretax profit margin | -1366.46% |
| net profit margin | -1366.46% |
| return on assets | -42.27% |
| return on equity | -49.53% |
| return on capital employed | -52.29% |
liquidity ratio | |
|---|---|
| current ratio | 7.58 |
| quick ratio | 7.58 |
| cash ratio | 0.94 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 94.76 |
| days of payables outstanding | 86.70 |
| cash conversion cycle | 8.06 |
| receivables turnover | 3.85 |
| payables turnover | 4.21 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.19 |
| debt equity ratio | 0.27 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.21 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -1.44 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.07 |
| cash per share | 2.41 |
| operating cash flow per share | -1.06 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -1.44 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -168.32 |
Frequently Asked Questions
When was the last time Fate Therapeutics, Inc. (NASDAQ:FATE) reported earnings?
Fate Therapeutics, Inc. (FATE) published its most recent earnings results on 12-11-2024.
What is Fate Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Fate Therapeutics, Inc. (NASDAQ:FATE)'s trailing twelve months ROE is -49.53%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Fate Therapeutics, Inc. (FATE) currently has a ROA of -42.27%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did FATE's net profit margin stand at?
FATE reported a profit margin of -1366.46% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is FATE's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 7.58 in the most recent quarter. The quick ratio stood at 7.58, with a Debt/Eq ratio of 0.27.